I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD16-negative, CD56-bright natural killer cell, human | 8 studies | 21% ± 6% | |
| B cell | 6 studies | 25% ± 6% | |
| natural killer cell | 6 studies | 22% ± 5% | |
| endothelial cell | 6 studies | 21% ± 4% | |
| plasmacytoid dendritic cell | 6 studies | 23% ± 7% | |
| epithelial cell | 5 studies | 32% ± 15% | |
| innate lymphoid cell | 5 studies | 18% ± 4% | |
| classical monocyte | 4 studies | 26% ± 10% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 22% ± 4% | |
| plasma cell | 4 studies | 24% ± 11% | |
| basal cell | 4 studies | 20% ± 4% | |
| naive B cell | 4 studies | 18% ± 2% | |
| non-classical monocyte | 3 studies | 30% ± 10% | |
| conventional dendritic cell | 3 studies | 32% ± 17% | |
| gamma-delta T cell | 3 studies | 27% ± 11% | |
| macrophage | 3 studies | 25% ± 1% |
